• AstraZeneca: Truqap Plus Faslodex Approved In US For HR Breast Cancer

    来源: NASDAQ US Markets / 17 11月 2023 03:04:07   America/New_York

    (RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that the U.S. Food and Drug Administration or FDA has approved its Truqap (capivasertib) in combination with Faslodex (fulvestrant) to treat patients with advanced hormone receptor or HR-positive breast https://www.nasdaq.com/articles/astrazeneca:-truqap-plus-faslodex-approved-in-us-for-hr-breast-cancer
分享